SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer

BACKGROUND: There is preclinical synergism between taxanes and MK-2206. We aim to determine the maximum tolerated dose, safety, and activity of combining MK-2206 and paclitaxel in metastatic cancer. METHODS: Patients received weekly doses of paclitaxel at 80mg/m2 on day 1, followed by MK-2206 orally...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Natl Cancer Inst
Hauptverfasser: Gonzalez-Angulo, Ana M., Krop, Ian, Akcakanat, Argun, Chen, Huiqin, Liu, Shuying, Li, Yisheng, Culotta, Kirk S., Tarco, Emily, Piha-Paul, Sarina, Moulder-Thompson, Stacy, Velez-Bravo, Vivianne, Sahin, Aysegul A., Doyle, Laurence A., Do, Kim-Anh, Winer, Eric P., Mills, Gordon B., Kurzrock, Razelle, Meric-Bernstam, Funda
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342675/
https://ncbi.nlm.nih.gov/pubmed/25688104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju493
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge